Details of the Drug

General Information of Drug (ID: DMWSZY9)

Drug Name

ASP0739

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04939701) A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1. U.S.National Institutes of Health.